<abstract xmlns="http://www.w3.org/1999/xhtml"><p>When it comes to tumor immunology, understanding of molecular pathways is rather important. During oncogenesis, many molecules should be taken in consideration altogether in context of a single malignancy. It is of a great significance to determine whether these molecules act synergistically or contrary, whether to understand a malignant disease more thoroughly, or even more important, to reveal new approaches of therapy. In this review, we discuss whether and how IL-33/ST2 and PD-1/PDL axis involve in antitumor immunity.</p></abstract>

When it comes to tumor immunology, understanding of molecular pathways is rather important. During oncogenesis, many molecules should be taken in consideration altogether in context of a single malignancy. It is of a great significance to determine whether these molecules act synergistically or contrary, whether to understand a malignant disease more thoroughly, or even more important, to reveal new approaches of therapy. In this review, we discuss whether and how IL-33/ST2 and PD-1/PDL axis involve in antitumor immunity.

Synergism of PDL/PD1 and IL33/ST2 Axis in Tumor Immunology

Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences

Experimental and Applied Biomedical Research (EABR)

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Synergism of PDL/PD1 and IL33/ST2 Axis in Tumor Immunology"}

When it comes to tumor immunology, understanding of molecular pathways is rather important. During oncogenesis, many molecules should be taken in consideration...

Synergism of PDL/PD1 and IL33/ST2 Axis in Tumor Immunology

Publié en ligne: 07 nov. 2019

Pages: 223 - 228

Reçu: 31 août 2018

Accepté: 04 sept. 2018

DOI: https://doi.org/10.2478/sjecr-2018-0033

Mots clés
IL-33, PD-1, tumor, antitumor immunity

© 2019 Marina Jovanovic et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Synergism of PDL/PD1 and IL33/ST2 Axis in Tumor Immunology

Publié en ligne: 07 nov. 2019

Pages: 223 - 228

Reçu: 31 août 2018

Accepté: 04 sept. 2018

DOI: https://doi.org/10.2478/sjecr-2018-0033

Mots clésIL-33, PD-1, tumor, antitumor immunity

© 2019 Marina Jovanovic et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
IL-33, PD-1, tumor, antitumor immunity